101 related articles for article (PubMed ID: 16831953)
1. NFATc1: a novel anabolic therapeutic target for osteoporosis.
Yeo H; McDonald JM; Zayzafoon M
Ann N Y Acad Sci; 2006 Apr; 1068():564-7. PubMed ID: 16831953
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin/NFAT signaling in osteoblasts regulates bone mass.
Winslow MM; Pan M; Starbuck M; Gallo EM; Deng L; Karsenty G; Crabtree GR
Dev Cell; 2006 Jun; 10(6):771-82. PubMed ID: 16740479
[TBL] [Abstract][Full Text] [Related]
3. The calcineurin-NFAT pathway and bone: intriguing new findings.
Stern PH
Mol Interv; 2006 Aug; 6(4):193-6. PubMed ID: 16960140
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation.
Yeo H; Beck LH; McDonald JM; Zayzafoon M
Bone; 2007 Jun; 40(6):1502-16. PubMed ID: 17392048
[TBL] [Abstract][Full Text] [Related]
5. NFAT and Osterix cooperatively regulate bone formation.
Koga T; Matsui Y; Asagiri M; Kodama T; de Crombrugghe B; Nakashima K; Takayanagi H
Nat Med; 2005 Aug; 11(8):880-5. PubMed ID: 16041384
[TBL] [Abstract][Full Text] [Related]
6. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
Tsuji-Naito K
Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NFAT increases osteoblast differentiation by increasing Fra-2 expression.
Zayzafoon M
J Musculoskelet Neuronal Interact; 2005; 5(4):347. PubMed ID: 16340132
[No Abstract] [Full Text] [Related]
8. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Hughes A; Rogers MJ; Idris AI; Crockett JC
Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
[TBL] [Abstract][Full Text] [Related]
9. [Genes involved in bone formation as a therapeutic target for osteoporosis].
Inoue D
Clin Calcium; 2005 May; 15(5):747-52. PubMed ID: 15876735
[TBL] [Abstract][Full Text] [Related]
10. New mechanisms and targets in the treatment of bone fragility.
Martin TJ; Seeman E
Clin Sci (Lond); 2007 Jan; 112(2):77-91. PubMed ID: 17155930
[TBL] [Abstract][Full Text] [Related]
11. [Hormones and osteoporosis update. Mechanisms of anabolic and catabolic effects of PTH on bone].
Kobayashi T
Clin Calcium; 2009 Jul; 19(7):911-8. PubMed ID: 19567985
[TBL] [Abstract][Full Text] [Related]
12. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
Bonnelye E; Chabadel A; Saltel F; Jurdic P
Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546
[TBL] [Abstract][Full Text] [Related]
13. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway.
Sato K; Suematsu A; Nakashima T; Takemoto-Kimura S; Aoki K; Morishita Y; Asahara H; Ohya K; Yamaguchi A; Takai T; Kodama T; Chatila TA; Bito H; Takayanagi H
Nat Med; 2006 Dec; 12(12):1410-6. PubMed ID: 17128269
[TBL] [Abstract][Full Text] [Related]
14. L: -carnitine fumarate and isovaleryl-L: -carnitine fumarate accelerate the recovery of bone volume/total volume ratio after experimetally induced osteoporosis in pregnant mice.
Patano N; Mancini L; Settanni MP; Strippoli M; Brunetti G; Greco G; Tamma R; Vergari R; Sardelli F; Koverech A; Colucci S; Zallone A; Grano M
Calcif Tissue Int; 2008 Mar; 82(3):221-8. PubMed ID: 18265928
[TBL] [Abstract][Full Text] [Related]
15. Ostreae Testa prevent ovariectomy-induced bone loss in mice by osteoblast activations.
Han SY; Lee JR; Kwon YK; Jo MJ; Park SJ; Kim SC; Lee HS; Ku SK
J Ethnopharmacol; 2007 Dec; 114(3):400-5. PubMed ID: 17905549
[TBL] [Abstract][Full Text] [Related]
16. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis.
Elabd C; Basillais A; Beaupied H; Breuil V; Wagner N; Scheideler M; Zaragosi LE; Massiéra F; Lemichez E; Trajanoski Z; Carle G; Euller-Ziegler L; Ailhaud G; Benhamou CL; Dani C; Amri EZ
Stem Cells; 2008 Sep; 26(9):2399-407. PubMed ID: 18583541
[TBL] [Abstract][Full Text] [Related]
17. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.
Bodine PV; Seestaller-Wehr L; Kharode YP; Bex FJ; Komm BS
J Cell Physiol; 2007 Feb; 210(2):352-7. PubMed ID: 17044082
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH
Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527
[TBL] [Abstract][Full Text] [Related]
19. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
20. Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis.
Bonnet N; Pierroz DD; Ferrari SL
J Musculoskelet Neuronal Interact; 2008; 8(2):94-104. PubMed ID: 18622078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
